BrainCheck Revolutionizes Cognitive Health Assessment with $15M Investment

BrainCheck, a digital health company founded by Stanford neuroscience professor David Eagleman, has secured a $15 million Series B extension to address the pressing need for rapid cognitive tests in the face of growing Alzheimer's disease risk. The company's innovative cognitive assessments and care plans are sold on a subscription basis to health care systems and payers, offering a sensitive and specific metric to assess age-related cognitive impairment in older adults. With millions of cases of undiagnosed mild cognitive impairment, BrainCheck's mission is to become the definitive standard cognitive assessment tool, leading a fundamental shift in how cognitive care is delivered. The recent funding round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, will fuel commercialization, clinical research, and integrations with electronic health records. BrainCheck's platform, including the BrainCheck Screen and BrainCheck Plan, streamlines screening, assessment, care planning, and monitoring, empowering providers and patients with clinically proven technology to intervene sooner and combat cognitive decline. The company's commitment to promoting, protecting, and preserving brain health aligns with the urgent need for early detection and intervention in cognitive diseases. With a focus on commercializing and scaling their digital cognitive assessment platform, BrainCheck aims to transform the way cognitive care is delivered, making it more proactive, personalized, and accessible. As the market experiences strong tailwinds with the advancement of disease-modifying therapies, BrainCheck is poised to capitalize on the momentum and drive innovation in cognitive health assessment.